3349 — Cosmos Pharmaceutical Balance Sheet
0.000.00%
- ¥711bn
- ¥717bn
- ¥965bn
- 83
- 28
- 99
- 83
Annual balance sheet for Cosmos Pharmaceutical, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | — | — | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 52,122 | 55,108 | 37,362 | 45,928 | 52,301 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,879 | 6,619 | 8,577 | 10,221 | 12,199 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 114,150 | 125,125 | 115,471 | 137,085 | 154,333 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 185,374 | 195,131 | 225,286 | 259,464 | 295,798 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 320,283 | 341,318 | 363,052 | 420,967 | 476,546 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 161,950 | 159,537 | 162,063 | 192,053 | 213,229 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 174,608 | 170,740 | 172,545 | 209,895 | 245,104 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 145,675 | 170,578 | 190,507 | 211,072 | 231,442 |
Total Liabilities & Shareholders' Equity | 320,283 | 341,318 | 363,052 | 420,967 | 476,546 |
Total Common Shares Outstanding |